Laboratory Genetics in Minnesota

2006 Publications from the Cytogenetics Laboratory

2006 Publications
Abstracts
Books and Book Chapters

2006 Publications

Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald G, Kantarjian HM, Pierce SR, Estey EH. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J of Haematol 13: 165-73, 2006.

Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res 2006 Nov 15; 66(22): 10683-90.

Brothman A., Schneider N, Saikevych I, Cooley L, Butler M, Patil S, Mascarello J, Rao K, Dewald G, Park, J, Persons D, Wolff D, Vance G: Cytogenetic heteromorphisms: G-band regions we've pondered for years. Arch of Pathol 130: 947-948, 2006.

Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Intergroup Radiation Therapy Oncology Group Trial 9402, Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup radiation therapy oncology group trial 9402. J Clin Oncol 2006 Jun 20; 24(18): 2707-14.

Chng W, Santana-Davila R, Van Wier S, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 20(5):807-813, 2006.

Chng WJ, Ketterling RP, Fonseca R. Analysis of genetic abnormalities in hyperdiploid myeloma provide insights into genetic evolution of aneuploid tumors. Genes Chromosomes Cancer 2006 Dec; 45(12):1111-20.

Dingli D, Schwager SM, Mesa RA, Li CY, Dewald G, Tefferi A: Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 106: 1985-1989, 2006.

Einerson RR, Law ME, Blair HE, Kurtin PJ, McClure RF, Ketterling RP, Flynn HC, Dogan A, Remstein ED. Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2. Leukemia 2006 Oct; 20(10):1790-9

Eklund EA, Sun L, Yang SP, Pasion RM, Thorland EC, Freeze HH. Congenital disorder of glycosylation Ic due to a de novo deletion and an hALG-6 mutation. Biochem Biophys Res Commun. 339(3):755-760, 2006.

Fink SR, Smoley SA, Stockero KJ, Paternoster SF, Thorland EC, Van Dyke DL, Shanafelt TD, Zent CS, Call TG, Kay NE, Dewald G: Loss of p53 is due to rearrangements involving chromosome 17p10 to 17p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet. 167: 177-81, 2006.

Fonseca R, Van Wier SA, Chng WJ, Ketterling RP, Lacy MQ, Dispenzieri A, Bersagel PL, Rajkumar SV, Greipp PR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006 Nov; 20(11):2034-40

Jaeckle KA, Ballman K, Rao R, Jenkins R, Buckner J. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of responsiveness. J Clin Oncol 2006 Mar 10; 24(8): 1246-52.

Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006 Oct 15; 66(20): 9852-61.

Klein RD, Thorland EC, Gonzales PR, Beck PA, Dykas DJ, McGrath JM, Bale AE. A multiplex assay for the detection and mapping of complex glycerol kinase deficiency. Clin Chem. 52(10):1864-1870, 2006.

Landstrom AP, Ketterling RP, Knudson RA, Tefferi A. Utility of peripheral blood D-FISH for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma 2006 Oct; 47(10): 2055-61.

Lebel RR, Roberson J, Van Dyke DL. Regarding Trisomy 18. Am J Med Genet 140A:964-965, 2006.

Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, Schild SE, Scheithauer BW, Jenkins RB, Buckner JC, Brown PD. Central neurocytoma: Management recommendations based on A 35-year experience. Int J Radiat Oncol Biol Phys 2006 Dec 20; [Epub ahead of print]

List A, Dewald G, Bennett J, Giagounadis A, Razs A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R for the MDS-003 Study Investigators: Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. N Eng J Med 355: 1456-65, 2006.

Litzow MR, Lee S, Bennet JM, Dewald G, Gallagher RE, Jain V, Paietta EM, Racevskis J, Rousey SR, Mazza JJ, Tallman MS: A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica 91: 1105-1108, 2006.

Macarenco RS, Erickson-Johnson M, Wang X, Jenkins RB, Nascimento AG, Oliveira AM. Cytogenetic and molecular genetic findings in dedifferentiated liposarcoma with neural-like whirling pattern and metaplastic bone formation. Cancer Genet Cytogenet 2006 Dec; 171(2): 126-9.

Mandal M, Srivastava A, Mahlum E, Desai D, Maran A, Yaszemski M, Jalal S, Gitelis S, Bertoni F, Damron T, Irwin R, O'Connor M, Schwartz H, Bolander M, Sarkar G. Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene 386:131-138, 2006.

Mensink KA, Ketterling RP, Flynn HC, Knudson RA, Lindor NM, Heese BA, Spinner RJ, Babovic-Vuksanovic D. Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature. J Med Genet 2006 Feb; 43(2):E8

Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A: A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points. Hematologica 91: 415-6, 2006.

Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A: JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res. 30 (11):1457-60, 2006.

Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald G:. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII / Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood. 2006 Dec 14; [Epub ahead of print].

Murillo H, Schmidt LJ, Karter M, Hafner KA, Kondo Y, Ballman KV, Vasmatzis G, Jenkins RB, Tindall DJ. Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence. Genes Chrom Cancer 2006 Jul; 45(7): 702-16.

Nelson BP, Treaba D, Goolsby, Williams S, Dewald G, Gordon L, Peterson LC: Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum. Leuk Lymph 47: 1352-1359, 2006.

Pardanani A, Ketterling RP, Li C-Y, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald G, Tefferi A: FIP1L1-PGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with Imatinib therapy, and a critical review of the literature: Leuk Res 30: 965-70, 2006.

Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB: HER2 testing by local, centeral, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2006 Jul 1; 24(19): 3032-8.

Perry CG, Young Jr. WF, McWhinney SR, Bei T, Stergiopoulos S, Knudson RA, Ketterling RP, Eng C, Stratakis CA, Carney JA. Functioning paraganglioma and gastrointestinal stromal tumor of the jejunum in three women: Syndrome or coincidence. Am J Surg Pathol 2006 Jan; 30(1):42-9.

Persons DL, Tubbs RR, Cooley LD, Dewald G, Dowling PK, Du E, Mascarello JT, Rao KW, Wilson KS, Wolff DJ, Habegger-Vance G: HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 130: 325-31, 2006.

Remstein ED, Dogan A, Einerson RR, Paternoster SF, Fink SR, Law M, Dewald G, Kurtin PJ: The Incidence and Anatomic Site Specificity of Chromosomal Translocations in Primary Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (MALT Lymphoma) in North America. Am J Surg Pathol 30:1546-53, 2006.

Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald G: Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated, early stage CLL. J Clin Oncol 24: 4634- 4641, 2006.

Soma LA, Gollin SM, Remstein ED, Ketterling RP, Flynn HC, Rajasenan KK, Swerdlow ST. Splenic small B-cell lymphoma with IGH/BCL3 translocation: A distinct entity? Hum Pathol 2006 Feb; 37(2): 218-30.

Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, Dewald G, Kaufmann SH: JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 20: 971-978, 2006.

Stockero KJ, Fink SR, Smoley SA, Paternoster SF, Shanafelt TD, Call TG, Zent CS, Van Dyke DL, Kay NE, Dewald G: Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia: Cancer Genet Cytogenet 166: 152-156, 2006.

Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006 Aug 15; 108(4): 1158-64.

Tefferi A, Strand JJ, Lasho TL, Elliott MA, Li CY, Mesa RA, Dewald G: Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. Cancer 106: 1739-1743, 2006.

Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. "Idiopathic" Eosinophilia with an Occult T-Cell Clone: Prevalence and Clinical Course. Leuk Res 2006 Nov 7; [Epub ahead of print]

Vance GH, Kim H, Hicks G, Cherry A, Higgins R, Hulshizer R, Tallman MS, Fernandez HF, Dewald G. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) Clinical Trial (E1900). Leuk Res 2006 Sep 20; [Epub ahead of print].

Welch RA, Salem-Elgharib S, Wiktor AE, Van Dyke DL, Blessed WB. Operator experience and sample quality in genetic amniocentesis. Am J Obstet Gynecol 194:189-91, 2006.

Wiktor AE, Stupca PJ, Van Dyke DL. ISCN (2005) — A Reference Guide. J Assoc Genet Technol 32(2):32-40, 2006.

Wiktor AE, Van Dyke DL, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, Dewald G: Preclinical Validation of fluorescence in situ hybridization assays for clinical practice: Genet Med 8: 16-23, 2006.

Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald G: Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with lenalidomide. Leuk Res. 2006 Nov 22; [Epub ahead of print]

Zou YS, Van Dyke DL, Thorland EC, Chhabra HS, Michels VV, Keefe JG, Lega MA, Feely MA, Uphoff TS, Jalal SM. Mosaic ring 20 with no detectable deletion by FISH analysis: Characteristic seizure disorder and literature review. Am J of Med Genet 140A:1696-1706, 2006.

Abstracts

Browning RE, Lucas DM, Geyer SM, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC: Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-cell CLL. 48th Annual Meeting of American Society of Hematology. Orlando, FL. December 2006. Blood 2006 Nov; 108(11 part 1):790a-1a.

Carlson AW, Knudson RA, Ketterling RP, Thorland EC. Duplication of the Williams syndrome critical region is rare in patients with speech and language delay phenotypes. American College of Medical Genetics Annual Meeting, San Diego, California, March 23-26, 2006.

Chhabra HS, Watson WJ, Katzmann JA, Lega MA, Shearer BM, Wiktor AE, Van Dyke DL, Ketterling RP, Jalal SM: Fetal nucleated RBC analysis using sequential cytoplasmic staining and multiple chromosomal FISH probes. American College of Medical Genetics Annual Meeting, San Diego, CA, March 23-26, 2006.

Colman H, Zhang L, Phillips H, Wei C, Nutt C, Louis DN, Carincross JG, Feuerstein BG, Yeh R-F, Jenkins RB, Aldape K. Meta-analysis of gene expression profiling data from glioblastoma tumor samples identifies a robust multigene classifier predictive of survival. AACR, 2006 Meeting.

Cousin MA, Knudson RA, Shearer BM, Kuffel DG, Jalal SM, Giannini CX, Ketterling RP: Determination of MYCN amplification status for neuroblastoma risk stratification using FISH probes on paraffin-embedded tissues. Association of Genetic Technologist 31st Annual Meeting, Baltimore, MD, June 1-4, 2006.

Fink S, Smoley SA, Paternoster SF, Stockero KJ, Nguyen LP, Nguyen PL, Hanson CA, Dewald GW: Frequency, Hematopathology and Detection of a New Isodicentric Variant of Deletion 20q. 48th Annual Meeting of American Society of Hematology. Orlando, FL. December 2006.. Blood 2006 Nov; 108(11 part 2):296b.

Gliem TJ, Zou Y, Mitchell E, Jalal SM. Analysis of a mosaic supernumerary marker chromosome inv dup(3)(q27-qter) with a neocentromere in a 4-year-old male. AGT Annual Meeting, Baltimore, MD, June 1-4, 2006.

Grever MR, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Appelbaum FR, Larson RA, Tallman MS, Gribben JG, Byrd JC. Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy (Abstract 6521). J Clin Oncol 2006 Jun; 24(18S): 342s

Jenkins RB, Ballman KV, Giannini C, Arusell RM, Blair H, Flynn H, Passe S, Brown PD, Shaw EG, Buckner JC. NCCTG 94-72-53: Diagnostic and prognostic significance of a t(1;19)(q10;p10) in patients (pts) with low-grade oligodendroglioma and astrocytoma. (Abstract 1505) J Clin Oncol 2006 Jun; 24(18S): 59s.

Jenkins RB, Blair H, Flynn H, Passe S, Law M, Ballman KV, Aldape K, Giannini C, Buckner JC. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q in human oligodendrogliomas. AACR, 2006 Meeting.

Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia. 48th Annual Meeting of American Society of Hematology. Orlando, FL. December 2006. Blood 2006 Nov; 108(11 part 1):15a.

Landstrom AP, Ketterling RP, Knudson RA, Dewald GW, Tefferi A. Additional cytogenetc abnormalities and/or Philadelphia chromosome metaphase mosaicism might adversely influence survival and imatinib response in chronic myeloid leukemia. American Society of Hematology 48th Annual Meeting, Orlando, FL, December 9-12, 2006.

Lega M, Babovic-Vuksanovic D, Zou Y, Gavrilov D, Jalal S: Implications of spontaneous excess expression of fra(16)(q22): An emerging syndrome? American College of Medical Genetics Annual Meeting, San Diego, CA, Poster, March 23-26, 2006.

List AF, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Nimer S, Zeldis J, Knight R: Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q. 48th Annual Meeting of American Society of Hematology. Orlando, FL. December 2006. Blood 2006 Nov; 108(11 part 1):78a.

Mahaffey VJ, Wiktor AE, Stockero KJ, Dewald GW: Study guide for fish, chromosomes and ISCN (2005) for hematologic malignancies. Association of Genetic Technologists Annual Meeting, Baltimore, MD, June 1-4, 2006. The Journal of the Association of Genetic Technologists 32 (3), 2006.

Mota RA, Marinello MJ, Hyzy MS, Jalal SM. Analysis of breakpoints by BACs of a prenatal case with apparently balanced reciprocal translocation and paracentric inversion. AGT Annual Meeting, Baltimore, MD, June 1-4, 2006

Pardanani A, Vaklavas C, Butterfield J, Ketterling R, Verstovek S, Kantarjian H, Tefferi A. "Idiopathic" eosinophilia with occult T-cell clone: Prevalence, FIP1L1-PDGFRA status, and clinical course. (Abstract 2701) Blood 2006 Nov; 108(11 part 1): 764A.

Raza A, Reeves JE, Feldman EJ, Deeg HJ, Dreisbach L, Schiffer CA, Shammo JM, Klimek VM, Greenberg PL, Bennett JM, Dewald GW, Zeldis JB, Wride K, Schmidt M, Knight RD, List AF: Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities. Session Type: Oral Session. 48th Annual Meeting of American Society of Hematology. Orlando, FL. December 2006. Blood 2006 Nov; 108(11 part 1):78a.

Shanafelt TD, Bone ND, Geyer SM, LaPlant B, Witzig TE, Schwager S, Dewald GW, Nowakowski GS, Tschumper RC, Zent CS, Call TG, Jelinek F, Kay NE: Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia. 48th Annual Meeting of American Society of Hematology. Orlando, FL. December 2006. Blood 2006 Nov; 108(11 part 1):786a.

Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer SG, Zent CS, Call TG, Jelinek DF, Kay DE, Dewald GW: Cytogenetic Abnormalities Can Change During the Course of the Disease Process in Chronic Lymphocytic Leukemia. Letter to Editor. Journal of Clinical Oncology 24: 3218-3219, 2006.

Shearer BM, Carlson AW, Thorland EC, Jalal SM, Ketterling RP. Reflex FISH testing for unsuccessful product of conception cultures: A retrospective analysis comparing 948 samples analyzed by FISH to 5,555 samples analyzed by conventional cytogenetics. American College of Medical Genetics Annual Meeting, San Diego, California, March 23-26, 2006.

Shearer BM, Keefe JG, De Celis C, Vendrell A, McClure RF, Thorland EC, Ketterling RP: Identification of a variant RARα gene rearrangement in a patient with acute promyelocytic leukemia. American Society of Human Genetics 56th Annual Meeting, New Orleans, LA, October 3-13, 2006.

Smoley SA, Nguyen LP, Dewald GW: Toward a comprehensive clinical fish test for deletions in 20q-. Association of Genetic Technologists Annual Meeting, Baltimore, MD, June 1-4, 2006. The Journal of the Association of Genetic Technologists 32 (3), 2006.

Thorland E, Glien T, Gonzales P, Wiktor A, Ketterling R: Large-scale blinded comparison of a commercially available array CGH platform to FISH for the analysis of subtelomeric abnormalities. American Society of Human Genetics 56th Annual Meeting, New Orleans, LA, October 3-13, 2006.

Tiedmann RE, Gonzalez-Paz N, Santana-Davila R, Chng WJ, Ketterling R, Gertz MA, Price-Troska T, Henderson K, Greipp PR, Rajkumar SV, Kyle R, Dispenzieri A, Lacy M, Fonseca R. Natural history, genetic aberrations and survival distinguish primary plasma cell leukemia from multiple myeloma with leukemic transformation. (Abstract 3587) Blood 2006 Nov, 108 (Part 1): 1024a.

Uphoff TC, Schuetzle MN, Bloxham JA, Spurbeck JL, Van Dyke DL, Hatten BA, Dawson DB: Microsatellite analysis of amniocytes reveals androgenetic: biparental mosaicism in association with placental mesenchymal dysplasia: A case report. American College of Medical Genetics Annual Meeting, San Diego, CA, March 23-26, 2006.

Van Dyke DL, Wei S, Monaghan KG, Blunden P, Mazzara P, Raghavan R, Oliveira AM, Wiktor AE, Keeney G, Ketterling RP: Nearly identical haploid karyotype in two tumors, masked by the larger pseudo-diploid subclone. American Society of Human Genetics 56th Annual Meeting, New Orleans, LA, October 3-13, 2006.

Vasmatzis G, Kosari F, Savci-Heijink CD, Klee E, Kube DM, Lamblin AF, Cheville JC, Connelly DP, Jenkins RB, Tindall D, Klee GG. Prediction of prostate cancer aggressiveness using gene expression signatures. Prostate SPORE Meeting, 2006.

Vogelbaum MA, Berkey B, Peereboom D, Giannini C, Jenkins R, Suh J, Brown P, Blumenthal D, Biggs C, Schultz C, Mehta M. RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas — relationship between 1p/19q status and progression-free survival. (Abstract 1517) J Clin Oncol 2006 Jun; 24(18S):62s.

Wolanskyj AP, Naseema G, Susan SM, Ketterling RP, Tefferi A. Cytogenetic abnormalities in essential thrombocythemia: Prevalence and prognostic significance. (abstract 3626) Blood 2006 Nov; 108(11 part 1): 1036a.

Zent CS, Bone ND, Call TG, Shanafelt TD, Geyer SM, Secreto CR, Jelinek DF, Tschumper RC, Dewald GW, Kay NK: Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis. 48th Annual Meeting of American Society of Hematology. Orlando, FL. December 2006. Blood 2006 Nov; 108(11 part 1):800a-1a.

Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald GW: Efficacy of Conventional Cytogenetics and FISH for EGR1 To Detect Deletion 5q in Hematological Disorders and To Assess Response to Treatment with Lenalidomide. 48th Annual Meeting of American Society of Hematology. Orlando, FL. December 2006. Blood 2006 Nov; 108(11 part 1):666a.

Zou YS, Mota RA, Jalal SM. 22q11.2 is a common breakpoint to multiple congenital reciprocal translocations about 20% of which have cryptic deletions. International Genetics Congress, Melbourne, Australia, 2006.

Zou YS, Van Dyke DL, Thorland EC, Chhabra HS, Keefe JG, Lega MA, Feely MA, Uphoff T, Jalal SM: A case of mosaic ring 20 with typical seizure disorder but without any detectable telomeric deletion by FISH probes: literature review and proposals. American College of Medical Genetics Annual Meeting, San Diego, CA, March 23-26, 2006.

Books and Book Chapters

Jenkins R: Clinical Molecular Pathology of Gliomas. In: Molecular Pathology in Clinical Practice, Leonard et al. Springer, New York, pp.291-296, 2006.

Monaghan KG, Van Dyke DL. Laboratory testing for Prader-Willi syndrome, in Management of Prader-Willi Syndrome, third edition, ed. by M. Butler, Baltimore, Lippincott Williams & Wilkins, p.74-93, 2006

Thorland EC, Adams SA, Van Dyke DL, Ketterling, RP. Complexities in ordering and interpreting genetic testing. Genetic Testing: Care, Consent, and Liability, ed. Neil F. Sharpe and Ronald F. Carter, New Jersey, John Wiley and Sons, 314-328, 2006.

Thorland, E.C., and Thibodeau, S.N. Colon: Hereditary Nonpolyposis Colon Cancer. In: Molecular Pathology in Clinical Practice, ed. Leonard, D.G., Bagg, A., Caliendo, A., Kaul, K., Snow-Bailey, K., Van Deerlin, V., Springer, New York, 223-232, 2006.

Van Dyke DL, Wiktor AE. Testing for sex chromosome mosaicism in Turner syndrome. In Wellness for Girls and Women with Turner Syndrome. ed. by Gravholt CH and Bondy CA. Netherlands, Elsevier, 2006.